|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0036525,
umls-concept:C0221099,
umls-concept:C0694888,
umls-concept:C0871261,
umls-concept:C0995188,
umls-concept:C1516213,
umls-concept:C1522484,
umls-concept:C1527249,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1880177,
umls-concept:C1880287,
umls-concept:C2911692
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-1-21
|
|
pubmed:abstractText |
It has been reported that KRAS mutations (and to a lesser extent KRAS mutations with the BRAF V600E mutation) negatively affect response to anti-epidermal growth factor receptor (EGFR) mAbs in metastatic colorectal cancer (mCRC) patients, while the biological impact of the EGFR pathway represented by PI3K/PTEN/AKT on anti-EGFR treatment is still not clear.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Nuclear Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/PI3KCA protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/PTEN Phosphohydrolase,
http://linkedlifedata.com/resource/pubmed/chemical/PTEN protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Transcription Factors,
http://linkedlifedata.com/resource/pubmed/chemical/cetuximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
pubmed-author:AndreolaSS,
pubmed-author:BajettaEE,
pubmed-author:BertarioLL,
pubmed-author:Di BartolomeoMM,
pubmed-author:FrattiniMM,
pubmed-author:GevorgyanAA,
pubmed-author:LampisAA,
pubmed-author:LewMM,
pubmed-author:LosaMM,
pubmed-author:OrsenigoMM,
pubmed-author:PerroneFF,
pubmed-author:PierottiM AMA,
pubmed-author:PilottiSS,
pubmed-author:RivaCC
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
84-90
|
|
pubmed:dateRevised |
2009-8-10
|
|
pubmed:meshHeading |
pubmed-meshheading:18669866-Adult,
pubmed-meshheading:18669866-Aged,
pubmed-meshheading:18669866-Antibodies, Monoclonal,
pubmed-meshheading:18669866-Antineoplastic Agents,
pubmed-meshheading:18669866-Colorectal Neoplasms,
pubmed-meshheading:18669866-DNA Mutational Analysis,
pubmed-meshheading:18669866-Disease-Free Survival,
pubmed-meshheading:18669866-Drug Resistance, Neoplasm,
pubmed-meshheading:18669866-Female,
pubmed-meshheading:18669866-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:18669866-Genes, erbB-1,
pubmed-meshheading:18669866-Genes, ras,
pubmed-meshheading:18669866-Humans,
pubmed-meshheading:18669866-Male,
pubmed-meshheading:18669866-Middle Aged,
pubmed-meshheading:18669866-Mutation,
pubmed-meshheading:18669866-Neoplasm Metastasis,
pubmed-meshheading:18669866-Nuclear Proteins,
pubmed-meshheading:18669866-PTEN Phosphohydrolase,
pubmed-meshheading:18669866-Signal Transduction,
pubmed-meshheading:18669866-Transcription Factors
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.
|
|
pubmed:affiliation |
Experimental Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
